Pulnovo Medical Announces $100M Financing Round with Medtronic Investment

The funding will support Pulnovo's global expansion of its innovative pulmonary artery denervation therapy.

Apr. 20, 2026 at 7:55am

Got story updates? Submit your updates here. ›

A highly detailed, photorealistic studio photograph of a sleek, metallic medical device component floating against a clean, white background, conveying the precision engineering and advanced technology of Pulnovo's PADN System.Pulnovo's innovative pulmonary artery denervation device represents a breakthrough in treating cardiopulmonary diseases through advanced medical technology.NYC Today

Pulnovo Medical, a pioneer in therapies for Pulmonary Hypertension and Heart Failure, has completed a $100 million strategic financing round. The round was led by a new investment from medical technology giant Medtronic, along with continued support from existing investors like EQT, Qiming Venture Partners, and Lilly Asia Ventures. The funding will advance Pulnovo's proprietary Pulmonary Artery Denervation (PADN) System, which has demonstrated clinical benefits in improving functional capacity and patient outcomes.

Why it matters

This financing represents a major milestone for Pulnovo, validating its innovative technology and clinical progress. The strategic partnership with Medtronic will help Pulnovo accelerate its global commercialization efforts for the PADN System, which targets a key underlying mechanism of cardiopulmonary disease. As Pulnovo expands its international footprint, this funding positions the company to deliver meaningful innovation to patients worldwide.

The details

Pulnovo's PADN System is a minimally invasive therapy designed to modulate overactivated sympathetic nerve activity that contributes to pulmonary vascular remodeling and cardiopulmonary disease progression. The therapy has been recognized in multiple international clinical guidelines and has demonstrated improvements in functional capacity and reductions in major adverse clinical events in global studies. Pulnovo has performed approximately 1,500 PADN procedures globally and has secured regulatory approvals in seven countries. In the U.S., Pulnovo has received FDA Breakthrough Device designation and has initiated two fully approved Investigational Device Exemption (IDE) trials.

  • Pulnovo completed the $100 million financing round on April 19, 2026.
  • Pulnovo has performed approximately 1,500 PADN procedures globally to date.
  • Pulnovo has secured regulatory approvals for the PADN System in seven countries.
  • Pulnovo has received FDA Breakthrough Device designation and initiated two IDE trials in the U.S.

The players

Pulnovo Medical

A pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, developing the proprietary Pulmonary Artery Denervation (PADN) System.

Medtronic

One of the world's largest medical technology companies, which made a strategic investment in Pulnovo's $100 million financing round.

Dr. Gregg Stone

Senior Faculty and Professor at Mount Sinai, leading the two Pulnovo IDE trials in the United States.

Andre Xiao

Pulnovo's new Chief Strategy Officer, who will lead global financing and strategy to support the company's next phase of growth.

Cynthia Chen

Chairlady and President of Pulnovo Medical.

Got photos? Submit your photos here. ›

What they’re saying

“Through the integration of industry expertise and long-term capital, Pulnovo is building a scalable growth model anchored in proprietary innovation, global clinical development, and strategic ecosystem partnerships. This financing marks a pivotal transition from a product-driven phase to a fully integrated global platform. As we continue to strengthen our capabilities across both clinical and technological fronts, we remain committed to delivering meaningful innovation to patients worldwide.”

— Cynthia Chen, Chairlady, President, Pulnovo Medical

What’s next

Pulnovo plans to use the proceeds from this financing to support ongoing clinical development, global regulatory submissions, international commercialization, and continued investment in the company's core technology platform. The company is also advancing commercialization of the PADN System across the European Union, Middle East, and China.

The takeaway

This strategic investment from Medtronic and the oversubscribed $100 million financing round represent a significant validation of Pulnovo's innovative pulmonary artery denervation technology and its potential to address unmet needs in cardiopulmonary diseases. The funding will enable Pulnovo to accelerate its global expansion and deliver its breakthrough therapy to more patients worldwide.